Combined CDC COVID-19/Influenza Test Amended to Include Promega Maxwell® RSC 48 and CSC 48 Instruments, Maxwell® RSC Viral Total Nucleic Acid Purification Kit

CDC COVID-19/流感联合测试已修改,包括Promega Maxwell®RSC 48和CSC 48仪器,Maxwell®RSC病毒总核酸纯化试剂盒

2021-01-14 09:00:11 BioSpace

本文共1799个字,阅读需5分钟

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005075/en/ The Promega Maxwell® CSC 48 (pictured), Maxwell® RSC 48 and Maxwell® RSC Viral Total Nucleic Acid Purification Kit are now authorized options for labs running the US Centers for Disease Control’s (CDC) Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. (Photo: Business Wire) The Promega Maxwell® RSC 48 benchtop instrument is an automated nucleic acid purification platform that processes up to 48 samples simultaneously. The Maxwell® CSC 48 nucleic acid extraction system is an in vitro diagnostic medical device specifically designed for clinical laboratories. The Maxwell® RSC Viral Total Nucleic Acid Purification Kit can be used with either instrument to purify viral RNA from SARS-CoV-2 test samples. Multiplex Tests for SARS-CoV-2, Influenza Multiplex tests, such as the Flu SC2 Multiplex Assay, can detect and differentiate RNA from SARS-CoV-2, influenza A virus, and influenza B virus from a single patient sample. This enables: labs to conserve materials while also processing more tests clinicians to differentiate between COVID-19 and flu, since symptoms can be similar health officials to conduct ongoing flu surveillance while also testing for SARS-CoV-2 “Multiplex molecular tests are crucial as the flu season overlaps with the COVID-19 pandemic, and we’re glad that Promega is able to continue to support laboratories by providing them more options as testing evolves and advances,” says Heather Tomlinson, Director of Clinical Diagnostics at Promega. Promega SARS-CoV-2 Support Maxwell® RSC 48, Maxwell® CSC 48, Maxwell® RSC Viral Total Nucleic Acid Purification Kit and GoTaq® Probe 1-Step RT-qPCR System are already included, for emergency use, in the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT–PCR Diagnostic Panel, which tests for COVID-19 only. Promega reagents, assays and benchtop instruments are being used around the world for SARS-CoV-2 testing, research, and vaccine development. Bioluminescent immunoassay to detect SARS-CoV-2 antibodies: The Lumit™ Dx SARS-CoV-2 Immunoassay is a qualitative IVD test intended to detect antibodies to SARS-CoV-2 in serum or plasma. Technology to accelerate COVID-19 testing: XpressAmp™ Direct Amplification Reagents allow labs to skip the RNA extraction step of the workflow. Reagents to enable testing an estimated 550 million samples: Since January 2020, Promega has rapidly increased production to support labs testing for SARS-CoV-2 worldwide. Tools used for COVID-19 applications are a small subset of the 4,000 products Promega manufactures and distributes globally, serving research, pharma, clinical, forensic and applied markets. These products are used for a myriad of applications in human health, disease, genetic identity, drug development, clinical diagnostics and more. To learn more about Promega SARS-CoV-2 products and Promega technical support visit: www.promega.com/covid19 About Promega Corporation Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s product portfolio of over 4,000 products support a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For over 40 years these tools and technologies have grown in their application and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information, visit www.promega.com View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005075/en/ Penny Patterson VP, Communications Promega Corporation Phone: (608) 274-4330 E-mail: penny.patterson@promega.com Source: Promega Corporation The Promega Maxwell® CSC 48 (pictured), Maxwell® RSC 48 and Maxwell® RSC Viral Total Nucleic Acid Purification Kit are now authorized options for labs running the US Centers for Disease Control’s (CDC) Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. (Photo: Business Wire)   View this news release and multimedia online at: http://www.businesswire.com/news/home/20210113005075/en
本新闻稿以多媒体为特色。在此查看完整版本:https://www.businesswire.com/news/home/20210113005075/en/ Promega Maxwell®CSC 48(如图),Maxwell®RSC 48和Maxwell®RSC病毒总核酸纯化试剂盒现已被授权用于运行美国疾病控制中心(CDC)新型冠状病毒流感(Flu SC2)多重检测的实验室。(图:商业连线) Promega Maxwell®RSC 48台式仪器是一种自动核酸纯化平台,可同时处理多达48个样品。Maxwell®CSC 48核酸提取系统是专为临床实验室设计的体外诊断医疗设备。Maxwell®RSC病毒总核酸纯化试剂盒可与任一仪器一起使用,从新型冠状病毒检测样本中纯化病毒RNA。 新型冠状病毒,流感多重检测 多重检测,如流感SC2多重检测,可以从单个患者样本中检测和区分新型冠状病毒病毒,甲型流感病毒和乙型流感病毒的RNA。这使得: 实验室在处理更多测试的同时节省材料 临床医生要区分COVID-19和流感,因为症状可能相似 卫生官员将继续进行流感监测,同时检测新型冠状病毒 Promega公司临床诊断部主任希瑟·汤姆林森说:“由于流感季节与COVID-19大流行重叠,多重分子检测至关重要,我们很高兴Promega公司能够继续支持实验室,随着检测的发展和进步,为他们提供更多的选择。” Promega新型冠状病毒支持 Maxwell®RSC 48,Maxwell®CSC 48,Maxwell®RSC病毒总核酸纯化试剂盒和Gotaq®探针1步RT-qPCR系统已包含在CDC 2019新型冠状病毒(2019-NCoV)实时RTPCR诊断面板中,用于紧急使用,该面板仅用于检测COVID-19。 Promega试剂,化验和台式仪器正在世界各地用于新型冠状病毒检测,研究和疫苗开发。 检测新型冠状病毒抗体的生物发光免疫测定法:Lumit™Dx新型冠状病毒免疫测定法是一种定性IVD试验,旨在检测血清或血浆中的新型冠状病毒抗体。 加速COVID-19测试的技术:Xpressamp™直接扩增试剂允许实验室跳过工作流程中的RNA提取步骤。 试剂可用于检测约5.5亿个样本:自2020年1月以来,Promega迅速提高了产量,以支持全球范围内的新型冠状病毒实验室检测。 用于COVID-19应用的工具是Promega在全球生产和分销的4000种产品中的一小部分,服务于研究,制药,临床,法医和应用市场。这些产品广泛应用于人类健康,疾病,基因识别,药物开发,临床诊断等领域。 欲了解更多有关Promega新型冠状病毒产品和Promega技术支持的信息,请访问:www.Promega.com/covid19 Promega公司简介 Promega公司是为生命科学行业提供创新解决方案和技术支持的领导者。该公司的产品组合超过4,000种产品支持一系列的生命科学工作的领域,如细胞生物学;DNA,RNA和蛋白质分析;药物开发;人类识别和分子诊断。40多年来,这些工具和技术的应用不断发展,今天被科学家和技术人员用于学术和政府研究,法医,制药,临床诊断,农业和环境测试等实验室。Promega公司总部设在美国威斯康星州麦迪逊市,在16个国家和地区设有分支机构,全球分销商超过50家。欲了解更多信息,请访问www.promega.com 在businesswire.com上查看源代码版本:https://www.businesswire.com/news/home/20210113005075/en/ 彭妮·帕特森 副总裁,通信 Promega公司 电话:(608)274-4330 电子邮件:penny.patterson@promega.com 资料来源:Promega Corporation Promega Maxwell®CSC 48(如图),Maxwell®RSC 48和Maxwell®RSC病毒总核酸纯化试剂盒现已被授权用于运行美国疾病控制中心(CDC)新型冠状病毒流感(Flu SC2)多重检测的实验室。(图:商业连线) 查看此新闻稿和多媒体联机: http://www.businesswire.com/news/home/20210113005075/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文